1287 related articles for article (PubMed ID: 22903953)
1. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
2. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
3. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Sader HS; Flamm RK; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
[TBL] [Abstract][Full Text] [Related]
4. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Farrell DJ; Flamm RK; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program.
Flamm RK; Sader HS; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S194-205. PubMed ID: 22903952
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Pfaller MA; Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).
Morrissey I; Leakey A
J Antimicrob Chemother; 2012 Jun; 67(6):1408-12. PubMed ID: 22357801
[TBL] [Abstract][Full Text] [Related]
11. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2013 Apr; 41(4):337-42. PubMed ID: 23466338
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
13. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
14. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
15. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
16. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.
Moisan H; Pruneau M; Malouin F
J Antimicrob Chemother; 2010 Apr; 65(4):713-6. PubMed ID: 20097788
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.
Sader HS; Flamm RK; Streit JM; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015 Apr; 59(4):2458-61. PubMed ID: 25645844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
